Abstract:Since their introduction, statin (HMG-CoA reductase inhibitor) drugs have advanced the practice of cardiology to unparalleled levels. Even so, coronary heart disease (CHD) still remains the leading cause of death in developed countries, and is predicted to soon dominate the causes of global mortality and disability as well. The currently available non-statin drugs have had limited success in reversing the burden of heart disease, but new information suggests they have roles in sizeable subpopulations of those affected. In this review, the status of approved non-statin drugs and the significant potential of newer drugs are discussed. Several different ways to raise plasma high-density lipoprotein (HDL) cholesterol (HDL-C) levels have been proposed, but disappointments are now in large part attributed to a preoccupation with HDL quantity, rather than quality, which is more important in cardiovascular (CV) protection. Niacin, an old drug with many antiatherogenic properties, was re-evaluated in two imperfect randomized controlled trials (RCTs), and failed to demonstrate clear effectiveness or safety. Fibrates, also with an attractive antiatherosclerotic profile and classically used for hypertriglyceridemia, lacks evidence-based proof of efficacy, save for a subgroup of diabetic patients with atherogenic dyslipidemia. Omega-3 fatty acids fall into this category as well, even with an impressive epidemiological evidence base. Omega-3 research has been plagued with methodological difficulties yielding tepid, uncertain, and conflicting results; well-designed studies over longer periods of time are needed. Addition of ezetimibe to statin therapy has now been shown to decrease levels of low-density lipoprotein (LDL) cholesterol (LDL-C), accompanied by a modest decrease in the number of CV events, though without any improvement in CV mortality. Importantly, the latest data provide crucial evidence that LDL lowering is central to the management of CV disease. Of drugs that inhibit cholesteryl ester transfer protein (CETP) tested thus far, two have failed and two remain under investigation and may yet prove to be valuable therapeutic agents. Monoclonal antibodies to proprotein convertase subtilisin/kexin type 9, now in phase III trials, lower LDL-C by over 50 % and are most promising. These drugs offer new ability to lower LDL-C in patients in whom statin drug use is, for one reason or another, limited or insufficient. Mipomersen and lomitapide have been approved for use in patients with familial hypercholesterolemia, a more common disease than appreciated. Anti-inflammatory drugs are finally receiving due attention in trials to elucidate potential clinical usefulness. All told, even though statins remain the standard of care, non-statin drugs are poised to assume a new, vital role in managing dyslipidemia.

High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease

Targeting high-density lipoproteins: update on a promising therapy

New Insights Into the Regulation of HDL Metabolism and Reverse Cholesterol Transport

High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease.

Using High-density Lipoprotein with New Therapeutic Techniques

Bridging the Gap Between the Bench and Bedside: Clinical Applications of High-density Lipoprotein Function

Drugs in development: targeting high-density lipoprotein metabolism and reverse cholesterol transport

Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels

HDL and arteriosclerosis: beyond reverse cholesterol transport

Section Review—Cardiovascular & Renal: Emerging Therapies in Atherosclerosis

High-Density Lipoprotein in Metabolic Disorders and Beyond: An Exciting New World Full of Challenges and Opportunities

Unravelling HDL—Looking beyond the Cholesterol Surface to the Quality Within

High-density lipoprotein cholesterol targeting for novel drug discovery: where have we gone wrong?

Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs

Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook

Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDL

Does Elevated High-Density Lipoprotein Cholesterol Protect Against Cardiovascular Disease?

Recent advances in physiological lipoprotein metabolism

Isolated low high density lipoprotein-cholesterol (HDL-C): implications of global risk reduction. Case report and systematic scientific review

High-Density Lipoprotein Subfractions Remodeling: A Critical Process for the Treatment of Atherosclerotic Cardiovascular Diseases